Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC

OBJECTIVES: More and more encouraging evidence revealed that immunotherapy could improve clinical outcomes in patients with previously treated non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) variations. However, immunotherapy is still a controversy for NSCLC patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ya, Yang, Zhengyu, Wang, Yanan, Hu, Minjuan, Zhang, Bo, Zhang, Yanwei, Qian, Fangfei, Zhang, Wei, Han, Baohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085497/
https://www.ncbi.nlm.nih.gov/pubmed/33937084
http://dx.doi.org/10.3389/fonc.2021.671228

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085497/
https://www.ncbi.nlm.nih.gov/pubmed/33937084
http://dx.doi.org/10.3389/fonc.2021.671228

Ejemplares similares